249 related articles for article (PubMed ID: 34877726)
1. Lower lymph node yield in axillary lymph node dissection specimens in breast cancer patients receiving neoadjuvant chemotherapy: Quality concern or treatment effect?
Ozao-Choy J; Moazzez A; Dauphine C
Breast J; 2021 Dec; 27(12):851-856. PubMed ID: 34877726
[TBL] [Abstract][Full Text] [Related]
2. Management of the axilla after neoadjuvant chemotherapy for clinically node positive breast cancer: A nationwide survey study in The Netherlands.
Vugts G; Maaskant-Braat AJ; de Roos WK; Voogd AC; Nieuwenhuijzen GA
Eur J Surg Oncol; 2016 Jul; 42(7):956-64. PubMed ID: 27107791
[TBL] [Abstract][Full Text] [Related]
3. Patterns in the Use of Axillary Operations for Patients with Node-Positive Breast Cancer After Neoadjuvant Chemotherapy: A National Cancer Database (NCDB) Analysis.
Srour MK; Tseng J; Luu M; Alban RF; Giuliano AE; Chung A
Ann Surg Oncol; 2019 Oct; 26(10):3305-3311. PubMed ID: 31342364
[TBL] [Abstract][Full Text] [Related]
4. The Impact of Neoadjuvant Chemotherapy on Axillary Surgical Management of Patients With Breast Cancer and Positive Axillary Lymph Nodes.
Cipolla C; Lupo S; Grassi N; Battaglia MC; Mesi C; Scandurra G; Gebbia V; Valerio MR
Anticancer Res; 2024 May; 44(5):2047-2053. PubMed ID: 38677748
[TBL] [Abstract][Full Text] [Related]
5. An ultrasound-based nomogram for predicting axillary node pathologic complete response after neoadjuvant chemotherapy in breast cancer: Modeling and external validation.
Zheng Q; Yan H; He Y; Wang J; Zhang N; Huo L; Liu Y; Wang L; Xu L; Fan Z
Cancer; 2024 Apr; 130(S8):1513-1523. PubMed ID: 38427584
[TBL] [Abstract][Full Text] [Related]
6. Axillary lymph node recurrence following wire-directed sentinel lymph node dissection for breast cancer patients with biopsy-proven axillary metastases prior to neoadjuvant chemotherapy at a safety net medical center.
Sargent RE; Siegel E; Ito F; Kramme K; Kraft E; Hendrix V; Carr AA; Nelson ME; Bian SX; Jayachandran P; Sener SF
J Surg Oncol; 2023 Jul; 128(1):9-15. PubMed ID: 36933187
[TBL] [Abstract][Full Text] [Related]
7. SAVI SCOUT® localization of metastatic axillary lymph node prior to neoadjuvant chemotherapy for targeted axillary dissection: a pilot study.
Baker JL; Haji F; Kusske AM; Fischer CP; Hoyt AC; Thompson CK; Lee MK; Attai D; DiNome ML
Breast Cancer Res Treat; 2022 Jan; 191(1):107-114. PubMed ID: 34652548
[TBL] [Abstract][Full Text] [Related]
8. Would Removal of All Ultrasound Abnormal Metastatic Lymph Nodes Without Sentinel Lymph Node Biopsy Be Accurate in Patients with Breast Cancer with Neoadjuvant Chemotherapy?
Lim GH; Gudi M; Teo SY; Ng RP; Yan Z; Lee YS; Allen JC; Leong LCH
Oncologist; 2020 Nov; 25(11):e1621-e1627. PubMed ID: 32537791
[TBL] [Abstract][Full Text] [Related]
9. Feasibility of targeted axillary dissection for de-escalation of surgical treatment after neoadjuvant chemotherapy in breast cancer.
Aragón-Sánchez S; Ciruelos-Gil E; López-Marín L; Galindo A; Tabuenca-Mateos MJ; Jiménez-Arranz S; Colmenero-Hernández M; Oliver-Pérez MR
Surg Oncol; 2022 Sep; 44():101823. PubMed ID: 36041377
[TBL] [Abstract][Full Text] [Related]
10. Development of a predictive score of axillary lymph node dissection based on targeted axillary dissection in patients with breast cancer diagnosis, affected lymph nodes, and neoadjuvant treatment.
Flores-Funes D; Aguilar-Jiménez J; Martínez-Gálvez M; Ibáñez-Ibáñez MJ; Carrasco-González L; Gil-Izquierdo JI; Chaves-Benito MA; Ayala-De La Peña F; Nieto-Olivares A; Aguayo-Albasini JL
Surg Oncol; 2021 Sep; 38():101629. PubMed ID: 34171793
[TBL] [Abstract][Full Text] [Related]
11. Axillary management for patients with breast cancer after neoadjuvant chemotherapy: Results of a survey among Brazilian breast surgeons.
Frasson AL; Resende HM; Lichtenfels M; Barbosa F; de Souza ABA; Miranda I; Falcone AB
J Surg Oncol; 2020 Nov; 122(6):1247-1251. PubMed ID: 33045117
[TBL] [Abstract][Full Text] [Related]
12. Advantages of preoperative localization and surgical resection of metastatic axillary lymph nodes using magnetic seeds after neoadjuvant chemotherapy in breast cancer.
Mariscal Martínez A; Vives Roselló I; Salazar Gómez A; Catanese A; Pérez Molina M; Solà Suarez M; Pascual Miguel I; Blay Aulina L; Ríos Gozálvez C; Julián Ibáñez JF; Rodríguez Martínez P; Martínez Román S; Margelí Vila M; Luna Tomás MA
Surg Oncol; 2021 Mar; 36():28-33. PubMed ID: 33285433
[TBL] [Abstract][Full Text] [Related]
13. A prospective feasibility study of sentinel node biopsy by modified Indigocarmine blue dye methods after neoadjuvant chemotherapy for breast cancer.
Kida K; Ishikawa T; Yamada A; Shimizu D; Tanabe M; Sasaki T; Ichikawa Y; Endo I
Eur J Surg Oncol; 2015 Apr; 41(4):566-70. PubMed ID: 25650249
[TBL] [Abstract][Full Text] [Related]
14. Nodal positivity and systemic therapy among patients with clinical T1-T2N0 human epidermal growth factor receptor-positive breast cancer: Results from two international cohorts.
Weiss A; Martínez-Sáez O; Waks AG; Laws A; McGrath M; Tarantino P; Portnow L; Winer E; Rey M; Tapia M; Prat A; Partridge AH; Tolaney SM; Cejalvo JM; Mittendorf EA; King TA
Cancer; 2023 Jun; 129(12):1836-1845. PubMed ID: 36951169
[TBL] [Abstract][Full Text] [Related]
15. Sentinel Node Biopsy in Patients With Breast Carcinoma Without Axillary Involvement at Diagnosis Receiving Primary Systemic Therapy.
García-Calvo L; Martí Álvarez C; Gutiérrez AH; García AB; Muñoz RA; Sánchez-Méndez JI
Clin Breast Cancer; 2023 Aug; 23(6):672-679. PubMed ID: 37331894
[TBL] [Abstract][Full Text] [Related]
16. A Novel Less-invasive Approach for Axillary Staging After Neoadjuvant Chemotherapy in Patients With Axillary Node-positive Breast Cancer by Combining Radioactive Iodine Seed Localization in the Axilla With the Sentinel Node Procedure (RISAS): A Dutch Prospective Multicenter Validation Study.
van Nijnatten TJA; Simons JM; Smidt ML; van der Pol CC; van Diest PJ; Jager A; van Klaveren D; Kam BLR; Lobbes MBI; de Boer M; Verhoef K; Koppert LB; Luiten EJT
Clin Breast Cancer; 2017 Aug; 17(5):399-402. PubMed ID: 28487053
[TBL] [Abstract][Full Text] [Related]
17. Does Neoadjuvant Chemotherapy in Clinical T1-T2 N0 Triple-Negative Breast Cancer Increase the Extent of Axillary Surgery?
Cortina CS; Lloren JI; Rogers C; Johnson MK; Cobb AN; Huang CC; Kong AL; Singh P; Teshome M
Ann Surg Oncol; 2024 May; 31(5):3128-3140. PubMed ID: 38270828
[TBL] [Abstract][Full Text] [Related]
18. Intraoperative sentinel node biopsy by one-step nucleic acid amplification (OSNA) avoids axillary lymphadenectomy in women with breast cancer treated with neoadjuvant chemotherapy.
Navarro-Cecilia J; Dueñas-Rodríguez B; Luque-López C; Ramírez-Expósito MJ; Martínez-Ferrol J; Ruíz-Mateas A; Ureña C; Carrera-González MP; Mayas MD; Martínez-Martos JM
Eur J Surg Oncol; 2013 Aug; 39(8):873-9. PubMed ID: 23711734
[TBL] [Abstract][Full Text] [Related]
19. How Often Is Treatment Effect Identified in Axillary Nodes with a Pathologic Complete Response After Neoadjuvant Chemotherapy?
Barrio AV; Mamtani A; Edelweiss M; Eaton A; Stempel M; Murray MP; Morrow M
Ann Surg Oncol; 2016 Oct; 23(11):3475-3480. PubMed ID: 27469123
[TBL] [Abstract][Full Text] [Related]
20. Sentinel lymph node biopsy after neoadjuvant chemotherapy predicts pathological axillary lymph node status in breast cancer patients with clinically positive axillary lymph nodes at presentation.
Takei H; Yoshida T; Kurosumi M; Inoue K; Matsumoto H; Hayashi Y; Higuchi T; Uchida S; Ninomiya J; Kubo K; Oba H; Nagai S; Tabei T
Int J Clin Oncol; 2013 Jun; 18(3):547-53. PubMed ID: 22588780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
